NDC product
BUPIVACAINE HCI
NDC 51662-1581 · HF Acquisition Co LLC, DBA HealthFirst
Key facts
| Product NDC | 51662-1581 |
|---|---|
| Proprietary name | BUPIVACAINE HCI |
| Nonproprietary name | BUPIVACAINE HCI |
| Substances | BUPIVACAINE HYDROCHLORIDE |
| Dosage form | INJECTION, SOLUTION |
| Route | INFILTRATION, PERINEURAL |
| Labeler | HF Acquisition Co LLC, DBA HealthFirst |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA207183 |
| Pharmacologic classes | Amide Local Anesthetic [EPC], Amides [CS], Local Anesthesia [PE] |
| Marketing start | Jul 10, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: